Cenerimod
Systemic Lupus Erythematosus (SLE)
Phase 3Partner-led (Viatris); 'SOS-AMI' program ongoing
Key Facts
Indication
Systemic Lupus Erythematosus (SLE)
Phase
Phase 3
Status
Partner-led (Viatris); 'SOS-AMI' program ongoing
Company
About Idorsia
Idorsia is a public Swiss biotech company that emerged from the demerger of Actelion following its acquisition by Johnson & Johnson in 2017. It has built a balanced portfolio with one commercial product (QUVIVIQ for insomnia) and several late-stage clinical assets, including TRYVIO/JERAYGO for resistant hypertension. The company's strategy focuses on unlocking the value of its commercial product, expanding strategic partnerships, advancing its differentiated pipeline, and maintaining financial discipline.
View full company profileTherapeutic Areas
Other Systemic Lupus Erythematosus (SLE) Drugs
| Drug | Company | Phase |
|---|---|---|
| CLN-978 | Cullinan Therapeutics | Phase 1 |
| Telitacicept | Vor Biopharma | Marketed |
| Dapirolizumab Pegol | Silence Therapeutics | Phase 3 |
| rese-cel (resecabtagene autoleucel) | Cabaletta Bio | Phase 1/2 |